{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-188851","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2023-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.905747+00:00","generated_at":"2026-06-13T07:16:53.095738+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"IO Biotech appoints Qasim Ahmad as CMO, promotes Eric Faulkner to CTO","bullets":["Qasim Ahmad, MD, appointed CMO effective July 15; previously Novartis SVP, US Head Clinical Development & Medical Affairs.","Eva Ehrnrooth transitions from CMO to Senior Clinical Advisor; departure not due to any disagreement.","Eric Faulkner promoted to CTO; previously Sr. VP CMC, will oversee CMC and Quality for commercial readiness.","Ahmad granted inducement option for 288,153 shares vesting over 4 years (25% cliff at year one).","Changes position company for BLA filing and next stage of growth; Ahmad based in US."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-188851","json":"https://secwatch.observer/filing/0001193125-23-188851.json","markdown":"https://secwatch.observer/filing/0001193125-23-188851.md","text":"https://secwatch.observer/filing/0001193125-23-188851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/0001193125-23-188851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/d523717d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:16:53.095738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"646d5c1e29","claim":"Qasim Ahmad was appointed as Chief Medical Officer at IO Biotech, Inc..","evidence_excerpt":"On July 15, 2023, IO Biotech, Inc. (the “Company”) appointed Qasim Ahmad, M.D. as the Company’s Chief Medical Officer, effective as of that same date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/0001193125-23-188851-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"d065c77f8b","claim":"Eva Ehrnrooth changed role as Senior Clinical Advisor at IO Biotech, Inc..","evidence_excerpt":"Dr. Ehrnrooth will now transition from her role as Chief Medical Officer to Senior Clinical Advisor, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/0001193125-23-188851-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transition"},{"label":"Role","value":"Senior Clinical Advisor"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}